Oncobiologics  has entered into a Master Services Agreement (MSA) with Sonnet BioTherapeutics, a privately held development stage biopharmaceutical company, and has officially launched its BioSymphony Platform-based contract development and manufacturing (CDMO) business. The terms of the MSA were not disclosed, but the MSA engages Oncobiologics to provide CDMO services for up to four drug product candidates over the next three years. “We are excited to sign our first CDMO contract to le...